Antiviral Therapies Market to growing at CAGR of 2.4% by 2026, Top Prominent Players: Bristol-Myers-Squibb, Abbott Laboratories

Surge in global burden of viral infection and stronger pipeline of anti-viral drugs are major factors that drive the growth of the anti-viral therapies market. Furthermore, increase in number of product approvals for combination therapy is expected to boost the market growth in the coming years

the global anti-viral therapies market garnered $38.31 billion in 2018, and is estimated to reach $46.21 billion by 2026, registering a CAGR of 2.4% from 2019 to 2026.

Download Detailed COVID-19 Impact Sample Report at @ https://www.alliedmarketresearch.com/request-for-customization/6643?reqfor=covid

Covid-19 Scenario:

• The revenue generated from anti-viral therapies will not affected by coronavirus pandemic owing to the essential treatments to be given for conditions including HIV, hepatitis, herpes virus, and others.
• People have become more conscious about viral infections amid the coronavirus pandemic across the globe.
• Anti-viral therapies are also beneficial to control the spread of coronavirus as they include the treatments on the basic symptoms of Covid-19.

Drivers, restraints, and opportunities

Increase in problem of viral infection and stronger pipeline of anti-viral drugs across the globe drive the growth of the global anti-viral therapies market. However, high cost of anti-viral therapies hinders the market growth. On the other hand, rise in number of product approvals for combination therapy create new opportunities in the coming years.

Download Report Sample @ https://www.alliedmarketresearch.com/purchase-enquiry/6643

The branded drugs segment to maintain its lead status in terms of revenue throughout the forecast period

Based on type, the branded drugs segment accounted for more than half of the global anti-viral therapiesmarket in 2018, and is expected to maintain its lead status in terms of revenue throughout the forecast period. This is due toavailability of large number of branded drugs for treating various viral infections.However, the generic drugssegment is estimated toportray the highest CAGR of 2.5% from 2019 to 2026, owing toincrease in number of branded drugs losing their patents

The nucleotide polymerase inhibitor segment to maintain its leadership position during the forecast period

Based on mechanism of action, the nucleotide polymerase inhibitor segment contributed to the highest market share with nearly two-fifth of the global anti-viral therapies market in 2018, and is estimated to maintain its leadership position during the forecast period. This is attributed toits increasing usage in Hepatitis C infection and is considered to be the first-line treatment for any viral infection. However, the reverse transcriptase inhibitors segment is estimated to generate the fastest CAGR of 3.1% from 2019 to 2026. This is attributed toincrease in FDA approvals for treating viral infection by reverse transcriptase inhibitor mechanism.

North America to maintain its dominant by 2026

Based on region, North Americaaccounted for the highest share based on revenue, holding for more than one-thirdof the global anti-viral therapies market in 2018, and is projected to maintain its dominant position throughout the forecast period. This is attributed to rise in incidences of infectious diseases across the region.However, Asia-Pacific is estimated toportray the fastest CAGR of 2.8% from 2019 to 2026, owing togrowing population base infected with infectious diseases in the region, presence of several generic pharmaceutical players, and increase in investment for drug development in South Asian countries.

To know more about the report, visit the website at @ https://www.alliedmarketresearch.com/anti-viral-therapies-market-A06278

The Major Key Players Are:

• F. Hoffmann-LaRoche Ltd.
• Gilead Sciences
• Glaxo Smith Kline
• Bristol-Myers-Squibb
• Abbott Laboratories
• Astra Zeneca plc
• Abb Vie Inc.
• Aurobindo Pharma Limited
• Johnson & Johnson
• Merck & Co.,Inc.

The other Key players Are:

• Schering-PloughCorporation
• Cipla
• DrReddy’s.

Similar Reports:

Medical Simulation Market : https://www.pharmiweb.com/press-release/2020-12-15/medical-simulation-market-size-is-generating-revenue-of-319-billion-by-2027

Brain Health Supplements Market : https://www.pharmiweb.com/press-release/2020-12-15/brain-health-supplements-market-value-to-grasp-581-billion-by-2023-registering-cagr-of-88-amr

Contact:

David Correa
5933 NE Win Sivers Drive
#205, Portland, OR 97220
United States
Toll Free (USA/Canada):
+1-800-792-5285, +1-503-894-6022, +1-503-446-1141
UK: +44-845-528-1300
Hong Kong: +852-301-84916
India (Pune): +91-20-66346060
Fax: +1-855-550-5975
help@alliedmarketresearch.com
Web: https://www.alliedmarketresearch.com

About Us:

Allied Market Research (AMR) is a market research and business-consulting firm of Allied Analytics LLP, based in Portland, Oregon. AMR offers market research reports, business solutions, consulting services, and insights on markets across 11 industry verticals. Adopting extensive research methodologies, AMR is instrumental in helping its clients to make strategic business decisions and achieve sustainable growth in their market domains. We are equipped with skilled analysts and experts, and have a wide experience of working with many Fortune 500 companies and small & medium enterprises.

This release was published on openPR.